RetinalGenix Technologies Begins Testing Remote Ocular Monitoring System

RetinalGenix Technologies Inc. has successfully begun patient imaging using the first prototype of its advanced remote ocular monitoring system. This device utilizes both near-infrared and green imaging modes to enhance visualization, with further refinements planned for the second prototype. Following this phase, the company will initiate design for manufacturing, moving the system closer to commercial availability.

Advancing Remote Eye Health Monitoring

The RetinalGenix imaging system is designed to enable secure, real-time remote monitoring, operating 24/7 from virtually any location. Upon completion of the final prototype, the company plans to install units in various healthcare and community settings, including:

       • Pharmacies and shopping malls

       • General practice and specialty medical offices

       • Hospitals, emergency rooms, and urgent care facilities

       • Nursing homes and independent living centers

Key Features of the Remote Ocular Monitoring System

       • No technician required for operation

       • No pupil dilation needed to capture a 40-degree field of vision

       • Simultaneous capture of both retinal and external eye images

       • Quick data access for remote physicians, allowing for immediate assessment

A Network of Retinal Specialists for Early Intervention

The system will connect with a specialized network of retinal specialists who will receive images on a contracted basis, assisting patients who may not currently have access to an eye care professional.

While the system is not intended for diagnostic purposes, it serves as a screening and monitoring tool, helping facilitate immediate follow-up, either through:

       • A physical examination

       • Scheduling an appointment with an eye care provider

CEO’s Vision for Preventing Blindness Through Real-Time Triage

Jerry Katzman, CEO of RetinalGenix Technologies, highlighted the need for faster triage in ophthalmic care:

“To prevent blindness, triage must occur in real-time, which typically does not happen under current circumstances. Additionally, the device must be available, affordable, accessible, and easy to use.”

Exploring Additional Applications for FDA-Approved Therapies

Beyond ocular imaging, RetinalGenix is also exploring opportunities to repurpose FDA-approved pharmaceuticals for the potential treatment of:

       • Dry age-related macular degeneration (AMD)

       • Diabetic retinopathy

       • Dementia

The company has submitted provisional patents for these treatments in both the United States and Europe.

Looking Ahead

With its remote ocular monitoring system in active testing and further innovations in ophthalmic drug therapy, RetinalGenix Technologies is working to enhance early detection, screening, and access to vision care, potentially preventing blindness through real-time intervention and advanced imaging technology.